August 8, 2024 11:14 AM EDT
Pharma
FDA+

Am­neal Phar­ma's ex­tend­ed-re­lease Park­ison's treat­ment clinch­es FDA ap­proval

Katherine Lewin

News Reporter

Am­neal Phar­ma­ceu­ti­cals’ ex­tend­ed-re­lease cap­sule for Parkin­son’s dis­ease has been ap­proved by the FDA fol­low­ing an ini­tial re­jec­tion last year.

The treat­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times